Skip to main content
Clinical Trials/ACTRN12606000147583
ACTRN12606000147583
Active, not recruiting
Phase 1

A prospective, randomised study to investigate if a patient-individualised dose regimen of enoxaparin reduces the incidence of bleeding and bruising as compared to conventional dosing in patients with ACS, AF, DVT and PE.

QHDAC0 sites120 target enrollmentApril 27, 2006

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
QHDAC
Enrollment
120
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 27, 2006
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
QHDAC

Eligibility Criteria

Inclusion Criteria

  • Any patient (male or female) initiated or about to be initiated on treatment doses of enoxaparin.

Exclusion Criteria

  • Pregnancy, anticoagulation in the past 7 days, abnormal liver function test (more than twice the usual range).

Outcomes

Primary Outcomes

Not specified

Similar Trials